Terminated PHASE2 INTERVENTIONAL 2-arm NCT04875975

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Sponsor: UCB Biopharma SRL

Conditions Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Interventions Placebo Rozanolixizumab

Updated 29 times since 2021 Last updated: May 29, 2025 Started: Sep 27, 2021 Primary completion: Mar 8, 2024 Completion: Apr 26, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.

Other terminated trials from UCB Biopharma SRL

See all terminations from UCB Biopharma SRL

This PHASE2 trial investigates Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis and is currently terminated or withdrawn. UCB Biopharma SRL leads this study, which shows 29 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

29 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Jun 2025 — Sep 2025 [monthly]

Terminated PHASE2
Sep 2024 — Jun 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jun 2024 — Jul 2024 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated

▶ Show 24 earlier versions

May 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE2
Apr 2024 — May 2024 [monthly]

Active Not Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2024 — Mar 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Jan 2023 — Mar 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Sep 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Apr 2022 — May 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Apr 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2
Jun 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Biopharma SRL

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Barcelona, Spain , Berlin, Germany , Bordeaux, France , Boston, United States , Bron, France , Brussels, Belgium , Cleveland, United States , Dallas, United States , Jacksonville, United States and 16 more locations